The Hidden Variable: A Case of Dasatinib-Induced Respiratory Failure

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Tyrosine kinase inhibitors targeting the BCR/ABL mutation are standard therapy for BCR/ABL positive acute lymphoblastic leukemia (ALL).
• Dasatinib is a potent multitargeted tyrosine kinase inhibitor effective in both imatinib-resistant and treatment-naïve Philadelphia chromosome-positive ALL.
• Philadelphia chromosome-positive ALL remains a significant challenge, particularly in elderly populations.

Observation:

• An elderly patient with Philadelphia chromosome-positive ALL was undergoing immunotherapy with dasatinib.
• The patient presented with acute hypoxic respiratory failure.

Findings:

• The patient's respiratory failure occurred in the context of active dasatinib treatment.
• This suggests a potential adverse event associated with dasatinib therapy in this patient demographic.

Implications:

• Clinicians should be vigilant for respiratory complications in elderly ALL patients receiving dasatinib.
• Further investigation into the mechanisms of dasatinib-induced respiratory toxicity is warranted.
• Risk-benefit assessment for dasatinib therapy in elderly patients may need to consider potential pulmonary adverse events.